Esperion Therapeutics (ESPR) Competitors $2.19 +0.02 (+0.92%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ESPR vs. GLPG, XNCR, EVO, ARQT, NRIX, KNSA, RCUS, IMCR, OCUL, and MESOShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Immunocore (IMCR), Ocular Therapeutix (OCUL), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Galapagos Xencor Evotec Arcutis Biotherapeutics Nurix Therapeutics Kiniksa Pharmaceuticals Arcus Biosciences Immunocore Ocular Therapeutix Mesoblast Esperion Therapeutics (NASDAQ:ESPR) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Which has more risk and volatility, ESPR or GLPG? Esperion Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ESPR or GLPG? 47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 1.0% of Esperion Therapeutics shares are owned by insiders. Comparatively, 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate ESPR or GLPG? Esperion Therapeutics presently has a consensus price target of $7.30, suggesting a potential upside of 233.33%. Galapagos has a consensus price target of $30.75, suggesting a potential upside of 14.91%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Is ESPR or GLPG more profitable? Galapagos has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-29.37% N/A -10.77% Galapagos N/A N/A N/A Does the media prefer ESPR or GLPG? In the previous week, Esperion Therapeutics had 18 more articles in the media than Galapagos. MarketBeat recorded 20 mentions for Esperion Therapeutics and 2 mentions for Galapagos. Galapagos' average media sentiment score of 0.68 beat Esperion Therapeutics' score of 0.51 indicating that Galapagos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Galapagos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, ESPR or GLPG? Galapagos has lower revenue, but higher earnings than Esperion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$295.45M1.46-$209.25M-$0.64-3.42Galapagos$260.09M6.78$229.12MN/AN/A Does the MarketBeat Community prefer ESPR or GLPG? Esperion Therapeutics received 154 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 69.98% of users gave Esperion Therapeutics an outperform vote while only 64.10% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformEsperion TherapeuticsOutperform Votes62069.98% Underperform Votes26630.02% GalapagosOutperform Votes46664.10% Underperform Votes26135.90% SummaryEsperion Therapeutics beats Galapagos on 9 of the 15 factors compared between the two stocks. Ad Brownstone ResearchMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$431.51M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-3.4210.5989.9717.18Price / Sales1.46195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book-0.575.094.784.78Net Income-$209.25M$151.83M$120.23M$225.60M7 Day Performance-2.67%-2.13%-1.92%-1.23%1 Month Performance-11.34%-3.10%11.49%3.36%1 Year Performance-6.01%11.54%30.57%16.60% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.9109 of 5 stars$2.19+0.9%$7.30+233.3%-3.5%$431.51M$295.45M-3.42240Analyst ForecastAnalyst RevisionNews CoverageGLPGGalapagos0.6163 of 5 stars$27.00+0.7%$30.75+13.9%-31.4%$1.78B$260.09M0.001,123XNCRXencor4.3204 of 5 stars$25.18+4.8%$36.56+45.2%+18.4%$1.76B$168.34M-7.51280EVOEvotec2.387 of 5 stars$4.69+4.5%$5.93+26.5%-60.5%$1.66B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.8599 of 5 stars$13.36+5.3%$15.50+16.0%+478.8%$1.56B$138.71M-7.58150Options VolumeNRIXNurix Therapeutics2.5066 of 5 stars$21.18+4.5%$30.35+43.3%+101.7%$1.50B$56.42M-6.97300News CoverageKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.60+2.0%$36.60+77.7%+15.4%$1.49B$384.10M-147.36220Positive NewsRCUSArcus Biosciences2.6476 of 5 stars$16.24+1.0%$34.00+109.4%-9.3%$1.49B$117M-5.11500News CoverageIMCRImmunocore2.4974 of 5 stars$29.51+2.1%$65.64+122.4%-51.4%$1.48B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.6452 of 5 stars$9.06+4.3%$16.71+84.5%+116.8%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.0377 of 5 stars$12.14+3.2%$11.50-5.3%+590.1%$1.39B$5.90M0.0080Analyst ForecastOptions VolumeNews CoveragePositive News Related Companies and Tools Related Companies Galapagos Competitors Xencor Competitors Evotec Competitors Arcutis Biotherapeutics Competitors Nurix Therapeutics Competitors Kiniksa Pharmaceuticals Competitors Arcus Biosciences Competitors Immunocore Competitors Ocular Therapeutix Competitors Mesoblast Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESPR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
